Great. Thanks, Matt.
programs to well as are that as excited XX. Slide in just on I&I relates data, X going And into Before about III the we as dermatomyositis. I really XX-week it are highlight to outlined NIU Phase brepo in briefly in wanted these tailwinds the
benefit JAK The both And first to can comfort risk and speaks XXXX is really than with think on have and that risk side physicians treated established morbidity fact a doubled profile of Priovant I is patients as this revenue. even of this inhibitors indications in benefit category, roughly is that that and these since which that includes patients quite the the profile significantly operating. terms agents the and left-hand less at those in you in see point, with
in one diseases the played terms over several have seen really of right-hand we've this morbidity out including those And indications that Priovant slide with revenue orphan concentrated of the be in those, side category is the very achieved high frame on these few also years, orphan launches operating then where prescriber high that as unmet this of with a given blockbuster high prevalence of the in indication base validated quick need source, revenue, but not time only morbidity, pricing. the and a can blockbuster disease, last
the to patients specialty the see so fourth Slide and concentrated of very of leading patients phenotype available developed are XX,XXX XX, base. this world money these blindness you centers. population, in And fits NIU quite prescriber Most morbidity, among in for prevalence, around working dedicated the turn really if very age cause to on that terms seen little patients uveitis high you of XXX,XXX
large the we therapy really HUMIRA reconfirms claims can TNF is particular, you from including effective clinical analysis number, receiving fewer biologics, patients And off-label number again did we patients and than a and of see with with Slide that with to TNF a we inhibitors XX, receiving And about TNF off-label TNF quite therapies. therapy is in NIU growing in new XX% IQVIA, includes trials HUMIRA which inhibitor, once patients from know experience supporting of both that in number of off-label between and XXXX, that real-world and NIU. large see other significantly only turning biologic and a XX,XXX
really it the the population. And and to also think try physicians the think for given that non that does speaks to both the potentially these the NIU off-label to in and and broader opportunity commercial the So we that to try large brepocitinib aggressively. patients data I our willingness therapies, work in find opportunity additional TNF urgency but interior something population speaks that the here of all feel refractory with data
that to turn data with I'll the context, itself. So
goal reminder with active treatment on patients of this the NIU, with X:X Just NIU, past non-interior registrational in as of paradigm rapidly Slide a as to XX of brief design prevent those the brepo enrolled well study patients X-week NEPTUNE need patients XX-milligram study XX-milligrams in received burst treatment is the are the given studies, and steroids. then to of study III are milligrams, avoid both per HUMIRA then randomized steroid consistent day Phase the for how including XX and of and sick off immediate primary a arms failure. all the are And tapered blindness in therapy to the risk
Notably, the including occurred as weeks. precedent it while study, week the in X taper studies, HUMIRA over a X, in over VISUAL occurred X reminder, XX weeks the NEPTUNE study, to
really efficacy. get to was study demonstrate for the for to a actually more designed difficult set So bar may higher brepocitinib it
And the so with generated. against that backdrop, excited results that were we're very
we failure have cases, data that XX, -- with study, which one on shared treatment rate the a primary And of the which Slide And the rate, both treatment on each is In left-hand I We what And here endpoint additional VISUAL previously. the you Matt side, the at failure see the from updated the measured arm. turning from walk the was start right XX. against mentioned, historical through only placebo that. the study. in now the slide, to then NEPTUNE to patient criteria week we've as side endpoint, primary XX-week
week excellent data sustained at So XX. to
using specifically on You'll XX% rate, the data that the X in XX well in to I arm study this failure months the it I the was year on over X.X the was you time for analysis. probably data of XX%, did and do the which includes rate placebo the a study VISUAL arm. now in and primary And excess Slide record rate VISUAL now, the Slide at that that report median was see this to with for was HUMIRA's we endpoint we under based that NEPTUNE compare although have to analysis which way X again, HUMIRA is, effective active AbbVie treatment published week not failure XX, from XX, on XX% with discontinuations X-year months most that call failure was prespecified
median that reinforcing the patient fails months. X again, before So
at So than just even X-month are benefit. not able receive of half the mark, more let alone patients the mark, to X-year
months. see in XX% a to median BREPO, treatment time it's over in arm, year, the to you And if And failure high-dose not rate, treatment in failure contrast dose not the X estimable get X.X XX did as then low months. are we even
failure. treatment on data exciting very So
data a XX-week XX, seeing data retinal is today. on And significant this up clinical also which as do No points, slightly. really very And to here most XX-milligram. data, you The XX on conference see from response biomarker XX were for right arm. the the field gold both low-dose which you the week leakage. not new weeks, already of quite -- you data, the patients relates for the the that fall. And And see at vascular was patients even XX, arm, is improvement but we side, see ocular the then on side, by increasing see particularly for presented really improving, Slide great XX it measurements arm left being the dose and high-dose top the standard wide we clear the that bottom week sustained the measuring then and what's high-dose actually time And row from inflammation, brepo XX supported to data which milligrams. of is only the geography retina milligrams at
community data resonates I quite ophthalmology bit very a here with So that exciting particular. the think in
XX. Slide to uveitis data to well time the edema one wanted as over consequence is macular inflammation. where and really of medium I is an this patients the share on data update particularly our to Turning because longer-term as develops XX-week edema macular think important
otherwise. of gotten be significantly levels short inflammation that one can control course, term, to So swelling the is not vision impairing the visual ultimately, macular low point even inflammation and uveitis macular the impaired of and acuity patients can time supply in to which, under if edema, ethane lead over of
baseline year And out you'll so XX-milligram data the recall, X had new it. had patients had the and resolution. see edema extent very And exciting the the patients in edema up very had week that at X and X it have you held to X resolution. that the no of can that here X did up, XX arm who we time well to see with eager patients developing quite of who we at as which quite those not held developed excited were But XX, a macular the in none resolution maintaining baseline, macular share to as of who
by the compares VISUAL from you not X again, And quite data viewed macular who did this study developed it the the macular at at year X half that by edema group, physicians super year. and were I X placebo was edema see onset being to at of of that's favorably effective is generally patients in which And real of had not supported is world baseline, the in have at months. them actually preventing HUMIRA,
looks patients. the to certainly like, small So of number see III in again, terms of We're the what to data drive. promising very potential but excited a Phase
course hope sustained time at even then in consistent as onset over X, rapid Slide the X very at at addition see the already to it the the arm, arm XX-milligram then and clear briefly on as I the begun this data here, particularly time, the week taper, further to in which to by And time ST looking looking data with steroid means that great you see, weeks very what great reinforce in response XX-milligram XX-milligram has with effect to clearly few to want of the X, well is while that a of out is dose you'd and just year. first the arm, see over is robustness
very about underway to Phase mentioned, II great already now months excited as and focused is year. not Phase share, a already at more months, to ago start. and excited excited excited now that the we X III Matt even after study data, we're Phase And So II we're of and after X few off and enrollment the the that announced as Priovant, and really on a
imagine, schematic closely on dose with technically see placebo. Phase X:X X here, I, -- very would the study, Phase for against Slide are only the advancing identical we is modeled You would for XX-milligram a This into so you randomized XX study X BREPO suggest XX patients but on single the with study one the substudies. III as as protocol,
XXX will So it reported substudy. per out CLARITY-X CLARITY-X be subjects as studies, X and
So XXX subjects total.
terms trials should to I we to uveitis the the as that data same really that controlled X, to failure, great and be of we've need we period a we've as time to and forward will points that of X what in in we done for the so had be end the saw new be no study that in as of measurements study. include expected will -- And taper endpoint bringing primary hopefully NEPTUNE standard as the clinical seen are on And which maintaining well, that rapid treatment the paper, demonstrate. is over that the data. despite secondary primary excited year are the all endpoint VISUAL setting the to steroid NEPTUNE same study, based and notably, of placebo And change be then therapies
have did support with filing. a incorporates we this productive summer, over And their to the it and deliver able results, we're NDA will meeting and confident successful FDA that an input, we're design
and be briefly a next Phase back going is program excited actually, of which I all NIU to readout and reading although fully we'll year. before dermatomyositis Phase BREPO's III of enrolled, NIU even lot highlight out the Matt we're before around to program, very excitement the all, Matt, III that, the NIU we're a about So have program, in did around really want as to as it there. potential mentioned, handing
patients similar excellence.
And these active walk adults therapies, prescriber get Slide terms just prevalence of and indication, attributes treatment a and blockbuster wanted we've around base funnel. available concentrated this steroids suggests there's NIU, to high percentage about is analysis XX,XXX half in patients the very are I treated highlight seen really for to these provides again our at that XX, more of modern in a of Slide the meets IVIG, centers what morbidity a a again, criteria kind really I'll patients the they claims hundred patients that U.S., to And a just nothing are of on the that of color in XX the next mostly very to slide. this high few on stand. bit being on are very on through This potential indication revenue of tertiary of conducive treated just rapid being on currently these and where
XX here, or as Notably, patients with -- treated dermatomyositis. injectable of here in referenced before for be steroids. You mentioned all but topical therapies actively cases the are the no and in around steroids see to late-stage on XXXX, oral
left-hand see the side And over XX% of these that treated on of you with the can slide are patients polypharmacy.
these goes So really the see limited right-hand patients treatments looks supposedly really over of -- therapies And that the XX% goal any chronically. efficacy of they yes. not how side, the XX receiving on you roughly greater terms it available same each the of how sparing than XX%, a terms biologics on oral are. IVIG just to and steroids then how I think of achieving -- patients they're steroid-sparing currently which and in day sick with groups are milligrams for some data, ISTs, or per different that in steroid of of
if of DM BREPO's So we early that adoption large rapid data for claims really readout, bolus potential analysis demand in approved we're launch. about the the this really and think a excited supports
just XX. tees the last We've data few with Slide us execution it up before Matt inflection been section study in just have that I that. some working Matt, to handing Phase follow to years really value to think major back wrap and upcoming the NIU behind development really starting up really in on GM, Priovant next mentioned, year, on III as my soon So over to
are with We at quite a indications in in beginning, of orphan also environment additional few planning an this I all doing start to mentioned the commercial XXXX. And studies as tailwinds. into
So excited really about ahead. what's
that, it And to I'll Matt. back with hand
